Gregory Russotti - 10 Mar 2025 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role
Title: Chief Technology and Manufacturing Officer
Signature
/s/ Douglas Carr, Attorney-in-Fact
Issuer symbol
IPSC
Transactions as of
10 Mar 2025
Net transactions value
-$1,451
Form type
4
Filing time
12 Mar 2025, 19:28:55 UTC
Previous filing
31 Jul 2024
Next filing
11 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IPSC Common Stock Sale $1,451 -2,360 -0.86% $0.6150 272,573 10 Mar 2025 Direct F1
transaction IPSC Common Stock Award $0 +120,000 +44% $0.000000 392,573 11 Mar 2025 Direct F2
holding IPSC Common Stock 92,773 10 Mar 2025 By Gregory Russotti 2021 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IPSC Stock Option (right to buy) Award $0 +120,000 $0.000000 120,000 11 Mar 2025 Common Stock 120,000 $0.6010 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Such sales were automatic and not at the discretion of the Reporting Person.
F2 Reflects the grant of RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F3 The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

Title: Chief Technology and Manufacturing Officer